Condition: Neoplasms · Advanced Solid Tumors · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Start Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| Centre Leon Berard | Lyon, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Hosp Univ Vall D Hebron | Barcelona, Spain | Recruiting |
| Hosp. Univ. 12 de Octubre | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06178614